<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>188Re (<z:chebi fb="0" ids="49882">Rhenium</z:chebi>) is easily obtained from an in-house 188W/188Re generator that is similar to the current 99Mo/99mTc generator, making it very convenient for clinical use </plain></SENT>
<SENT sid="1" pm="."><plain>This characteristic makes this radionuclide a promising candidate as a therapeutic agent </plain></SENT>
<SENT sid="2" pm="."><plain>Polyethylenimine (<z:chebi fb="0" ids="53231">PEI</z:chebi>) is a cationic polymer and has been used as a gene delivery vector </plain></SENT>
<SENT sid="3" pm="."><plain>Positively charged materials interact with cellular blood components, vascular endothelium, and plasma proteins </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, the authors investigated whether intratumoral injection of 188Re labeled transferrin (Tf)-<z:chebi fb="0" ids="53231">PEI</z:chebi> conjugates exert the effect of radionuclide therapy against the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>When the diameters of the Ramos <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (human Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) xenografted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> reached approximately 1 cm, 3 kinds of 188Re bound compounds (HYNIC-<z:chebi fb="0" ids="53231">PEI</z:chebi>-Tf, HYNIC-<z:chebi fb="0" ids="53231">PEI</z:chebi>, 188Re perrhenate) were injected directly into the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>There were increases in the retention of 188Re inside the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> when <z:chebi fb="0" ids="53231">PEI</z:chebi> was incorporated with 188Re compared to the use of free 188Re </plain></SENT>
<SENT sid="7" pm="."><plain>The 188Re HYNIC-Tf-<z:chebi fb="0" ids="53231">PEI</z:chebi> showed the most retention inside the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (retention rate=approximately 97%) </plain></SENT>
<SENT sid="8" pm="."><plain>H&amp;E stain of isolated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues showed that 188Re labeled HYNIC-<z:chebi fb="0" ids="53231">PEI</z:chebi>-Tf caused extensive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>These results support 188Re HYNIC-<z:chebi fb="0" ids="53231">PEI</z:chebi>-Tf as being a useful radiopharmaceutical agent to treat <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> when delivered by intratumoral injection </plain></SENT>
</text></document>